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Background: The aim of this study is to evaluate eye structures and function in patients 
receiving iron chelating therapy and to assess whether a correlation exists between the onset 
of ocular alterations and the intake of iron chelating drugs.
Methods: A prospective cohort study was performed. Eighty-eight patients, composed of 
children and adults with thalassemia major (TM) who are taking or had taken iron chelating 
drugs (deferoxamine, deferiprone or deferasirox), have been initially enrolled in the study. 
The final sample featured 80 patients, including 18 children and 62 adults. These subjects 
received an eye examination to evaluate intraocular pressure (IOP), best corrected visual 
acuity (BCVA), the presence of refractive defects, cornea, anterior chamber, lens, fundus 
oculi, visual field and mean retinal nerve fiber layer (RNFL) thickness. Logistic regression 
model analysis was performed in order to assess any correlation. In addition, a literature 
search regarding the relation between iron chelating drugs and ocular adverse events was 
carried out to compare the results obtained with the evidence in the literature.
Results: Logistic regression did not report a significant correlation between the intake of 
iron chelating drugs and the onset of anterior ocular segment alterations, lens opacities, 
retinal diseases, optical neuropathies, astigmatism, visual field and RNFL thickness defects. 
Logistic regression returned a statistically significant correlation between myopia and iron 
chelation therapy (p-value 0.04; OR 1.05) and also between presbyopia and total duration of 
therapy with deferoxamine (p-value 0.03; OR 1.21). Although intraocular pressure levels 
remained within the normal range, a significant correlation with the length of deferoxamine 
therapy has been found (p-value 0.002; association coefficient −0.12). A negative correlation 
between deferiprone and presbyopia has also been observed.
Conclusion: Iron chelation therapy is not associated with severe visual function alterations. 
Limitation of deferoxamine treatment can help prevent ocular complications. Deferiprone 
and/or deferasirox may be preferable, especially in patients over age 40 years.
Keywords: iron chelation, ocular adverse effects, deferiprone, deferasirox, deferoxamine
Background
Thalassemia major (TM), a blood disorder inherited in an autosomal recessive 
manner, is caused by mutation of the β globin chain gene1,2 which leads to 
a severe anemic state.3 Conservative therapy with regular red blood cell (RBC) 
transfusion4–7 is effective in replacing missing hemoglobin but results in progres-
sive iron overload with long-term toxicity.8 For this reason, this treatment is 
combined with daily intake of iron chelating agents9–12 (deferoxamine,4 
deferiprone13 or deferasirox).13–15
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While iron chelating drugs are essential for overall 
survival and complication-free survival, they carry consid-
erable side effects.13,16,17 Among the less studied ones are 
ophthalmic complications: various case reports18–28 
described a relationship between initiation of chelation 
therapy and onset of ocular symptoms. However, no sys-
tematic reviews published to date indicated whether these 
events are frequently related to specific risk factors or 
preventable. Furthermore, it has not yet been established 
whether ophthalmological complications may be related to 
the dosage of chelating agents or their intake time. The 
majority of articles refer to deferoxamine,16,20–41 while 
data about deferiprone18,19,32 and deferasirox42,43 are 
poor and do not allow to draw any conclusions.
The aim of this observational study is to evaluate the 
eye structures and function in patients receiving iron che-
lating therapy and to determine whether a correlation 
exists between the onset of ocular alterations related to 
iron overload and the intake time and/or dosage of iron 
chelating drugs. In addition, we searched medical data-
bases to assess whether the prevalence of such alterations 
in patients treated with iron chelating agents is higher than 
healthy population.
Methods
This prospective cohort study was approved by our insti-
tutional ethics committee (San Luigi Gonzaga Ethics 
Committee). Written consent to participate was collected 
by all participants upon registration. All procedures in this 
study concerning his conduction and documentation were 
performed in conformity with the ethical principles set out 
in the Helsinki Declaration and its revisions. All partici-
pants were informed about the purpose of the study; 
a parent or legal guardian of the children provided 
informed consent.
Patients
The study population was composed of children and adults 
with Thalassemia Major (TM), who were taking or had 
taken iron chelating drugs. These patients were followed at 
our institution, San Luigi Gonzaga University Hospital 
(Orbassano, Turin), the Regional Reference Center for 
Hemoglobinopathies in Piedmont and Valle d’Aosta. 
Inclusion criteria were as follows: diagnosis of TM and 
in regular follow-up; regular transfusion therapy and che-
lation therapy with deferoxamine, deferiprone and/or 
deferasirox; good compliance with chelation therapy, 
with respect by the patient of the intake times and doses 
of chelating drugs indicated by the medical staff. 
Exclusion criteria were as follows: diabetic retinopathy, 
glaucoma and any form of ocular alteration pre-existing 
the start of iron chelation therapy.
Initially, 88 patients were enrolled in the study. Data 
were collected via direct interview and with the help of the 
Digital Clinical Folder Management Software 
WebTHAL.44 Collected data included demographic (gen-
der, age, ethnicity) and medical history regarding the dis-
ease (date of diagnosis), its complications and treatment 
(first transfusion date, initiation of chelation therapy, 
intake times and doses of chelating agents, splenectomy 
and transplant dates).
Eight of the 88 patients initially enrolled in the study were 
excluded: 2 adults who did not report diabetic retinopathy 
and 6 children under the age of 5 years who did not collabo-
rate during the eye examination. The final sample featured 80 
patients (160 eyes), including 18 children (8 girls and 10 
boys; mean age 10.6 ±4 years) and 62 adults (40 women and 
22 men; mean age 38.4 ±7.2 years) (Table 1).
Eye Examination
All patients received eye examinations to evaluate intrao-
cular pressure (IOP), best-corrected visual acuity (BCVA), 
refractive defects (including the presence of presbyopia), 
cornea, anterior chamber, lens, and fundus oculi.
IOP was measured with a Topcon CT-80 air jet tonometer 
for noninvasive examination and screening. BCVA, refractive 
defects and presbyopia were measured and evaluated first 
using a Shin Nippon automatic refractometer and then 
Snellen eye charts with letters or Albini’s “E”. Cornea, anterior 
chamber and lens were observed using a Haag Streit 900 slit 
lamp. Fundus oculi examination was performed at the slit 
lamp with the use of additional Volk lenses after mydriasis 
induction with phenylephrine 1% + tropicamide 0.5% eye 
drops in adults, or tropicamide 1% in children. Then, all 
subjects received an evaluation of both visual field and mean 
peripapillary retinal nerve fiber layer (RNFL) thickness. Both 
manual (Goldmann perimeter, Haag-Streit, Bern, Switzerland) 
and automated methods (Humphrey Field Analyzer, Carl 
Zeiss Meditec, Berlin, Germany) were applied to visual field 
examination. The mean peripapillary RNFL thickness assess-
ments were performed through ocular Spectral-Domain 
Optical Coherence Tomography (Spectralis HRA + OCT; 
Heidelberg Engineering, Heidelberg, Germany).
Normal values were defined according to standard 
parameters (Table 2).
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Statistical Analysis
To determine whether a statistically significant correlation 
exists between ophthalmological alterations and intake 
time/maximum intake dose of chelating drugs, we used 
logistic regression models with monoparametric analysis 
that included variables of primary interest. The variables 
related to chelating agents’ intake were re-evaluated with 
multiparametric tests that accounted also for age, sex, 
duration of transfusion therapy and adverse events.
All analyses were performed with SPSS 20.0 statistical 
software.
Literature Search
Literature search was performed on PubMed and Cochrane 
Library databases with the string: (((((((((“Iron Chelating 
Agents”[Mesh]) OR “Iron Chelator*”) OR “Iron 
Chelation*”) OR “Iron Chelate*”)) OR ((((((exjade) OR 
deferasirox) OR deferoxamine) OR desferal) OR deferi-
prone) OR Ferriprox))) AND ((((((((“Eye Diseases”[Mesh] 
Table 1 Features of Population in Study
Children Adults Total
SEX 8 F + 10 M 40 F + 22 M 48 F + 32 M
AGE (years) 10.6 ± 4.0 (4.2–17.2) 
9.0–10.2 – 12.8
38.4 ± 7.2 (18.5–50.0) 
36.3–39.9 – 42.5
32.2 ± 13.4 (4.2–50.0) 
20.8–38.8 – 41.4
TRANSFUSIONS (years) 9.1 ± 3.2 (4.0–14.2) 
7.8–9.0 – 11.3
37.3 ± 7.7 (18.1–49.4) 
34.2–39.2 – 42.0
30.9 ± 13.7 (4.0–49.4) 
19.3–38.0 – 40.6
SPLENECTOMY (%) 0% 71% 55%
TRANSPLANTATION (%) 11% 0% 2.5%
COMPLICATIONS (%) 33.3% 100% 85%
TOTAL CHELATING TIME (years) 7.9 ± 2.9 (2.8–11.5) 
6.6–8.3 – 10.3
32.8 ± 7.8 (14.0–45.8) 
29.0–35.2 – 36.7
27.2 ± 12.6 (2.8–45.8) 
17.7–31.1 – 35.9
DEFEROXAMINE TIME (years) 3.9 ± 1.4 (2.5–6.3) 
2.8–3.3 – 5.0
20.3 ± 8.0 (7.0–36.8) 
13.8–21.6 – 26.0
16.6 ± 9.9 (2.5–36.8) 
7.5–15.0 – 23.9
DEFEROXAMINE DOSE (mg/Kg/die) 32.9 ± 2.6 (29.0–38.0) 
33.0–33.0 – 34.0
36.1 ± 7.5 (15.0–53.0) 
31.0–38.0 – 39.75
35.4 ± 6.8 (15.0–53.0) 
31.0–36.5 – 39.0
DEFERIPRONE TIME (years) 0 6.5 ± 7.2 (0.0–21.1) 
0.8–3.0 – 12.8
5.0 ± 6.9 (0.0–21.1) 
0.0–1.4 – 6.6
DEFERIPRONE DOSE (mg/Kg/die) 0 73.7 ± 37.7 (0.0–118.0) 
51.5–91.0 – 102.0
57.2 ± 45.3 (0.0–118.0) 
0.0–73.5 – 101.3
DEFERASIROX TIME (years) 4.0 ± 2.3 (0.0–7.0) 
3.3–4.5 – 5.2
6.0 ± 4.3 (0.0–14.1) 
2.0–6.1 – 8.1
5.6 ± 4.0 (0.0–14.1) 
2.0–5.9 – 7.6
DEFERASIROX DOSE (mg/Kg/die) 25.8 ± 10.0 (0.0–35.0) 
25.0–28.0 – 31.0
25.2 ± 10.1 (0.0–44.0) 
21.0–29.0 – 31.0
25.4 ±10.0 (0.0–44.0) 
21.0–28.5 – 31.0
Table 2 Estimated Parameters
Method of 
Execution
Normality
Cornea and 
anterior chamber
Slit lamp No abnormalities or 
minor physiological 
alterations
Lens Slit lamp No opacity
Posterior chamber 
and fundus oculi
Slit lamp with 
additional lenses, 
in midriasis
Papilla, vases and retina 
morphology within 
physiological limits
Visual acuity/ 
Refractive errors 
and presbyopia
Eye charts 10/10 without lens need
IOP Air jet tonometer </= 21 mmHg
Visual field Manual and 
computerized
No shrinkage or stricture
RNFL thickness Spectral-domain 
OCT
98.1 ± 10.9 μm
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OR “eye disease*”)) OR “ocular disease*”) OR “retinal 
diseases”) OR “crystalline lens”[Title/Abstract]) OR “visual 
field”[Title/Abstract]) OR “intraocular pressure”[Title/ 
Abstract]) OR ophthalmic[Title/Abstract]))) AND 
((“Thalassemia”[Mesh]) OR “beta-Thalassemia”[Mesh] OR 
“beta Thalassemia” OR “thalassemia major” OR “beta Type 
Microcytemia” OR “Mediterranean Anemia” OR 
“Hemoglobin F Disease” OR drepanocytosis OR “Cooley’s 
Anemia” OR “Cooley Anemia”).
In addition, we searched the same platforms for epide-
miological data of ocular alterations within the general 
population.
The last search was done on November 30, 2020.
With our search string, we found 42 articles; an addi-
tional one was found after removing the last section from 
the string (concerning TM). Only 24 of these articles were 
included as they were relevant to the subject and consid-
ered the evaluated parameters. Four articles were impor-
tant to the topic but did not focus on evaluated parameters; 
five were unavailable as full text because outdated; resi-
dual articles were excluded because irrelevant to the sub-
ject or published in a foreign language (Figure 1).
Results
The duration of transfusion therapy in children ranged from 
4.0 to 17.2 years. None of them underwent splenectomy; one 
patient was waiting for transplantation. Despite their young 
age, six patients had already developed complications related 
to the underlying disease (cholelithiasis, kidney stones, 
osteoporosis). The overall duration of chelation therapy 
depended on the patients’ age (median 8.3 years, first and 
third quartiles 6.6 and 10.3 years, respectively). None of the 
patients received deferiprone; the drug used the longest was 
deferasirox, at a maximum dose of 25.8 ± 10 mg/kg/day.
The duration of transfusion therapy in adults ranged from 
18.5 to 50.0 years. Forty-four patients underwent splenect-
omy; none received bone marrow transplantation. 
Complications related to TM and previous therapies included 
cholelithiasis, osteoporosis, kidney stones, HCV infection, 
pituitary gland hypofunction, hypothyroidism, hypoparathyr-
oidism, chronic hepatopathy, cardiomyopathy, neurosensorial 
deafness, impaired glucose tolerance or type II diabetes, and 
slowed growth. The median total duration of chelation ther-
apy was 35.2 years (first and third quartiles 29.0 and 36.7 
years, respectively). The drug that was taken the longest was 
deferoxamine, at a maximum dose of 36.1 ± 7.5 mg/kg/day.
Cornea and Anterior Chamber
Only four among adult patients (2.5% of the sample) 
showed alterations in the front chamber, with bilateral 
ectropion uveae. Logistic regression returned no 
Figure 1 Process of bibliographical article selection.
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significant p-values for the correlation between alteration 
and treatment duration or doses (Figure 2.1).
Four articles reported the effects of iron chelating agents 
on the cornea and anterior chamber. None of the four clinical 
trials found statistically significant alterations,29,30,35,45 and 
a single article described alterations as being more frequent 
in the control group than in the chelated patients.45
Lens
Among the studied subjects, only two eyes (1.25% of the 
sample) of a child, who had never taken deferiprone, had 
a mild sutural opacity. Logistic regression returned no 
significant p-values for the correlation between this altera-
tion with treatment duration and dosage (Figure 2.2).
Nine articles in the literature described lens anomalies 
during iron chelation therapy. However, five studies found 
no correlation between treatment and lens alterations41,45 
or, the observed prevalence was not different from the one 
reported in the general population.30,31,42,43 Three case 
reports described four cases of lens opacities, three of 
which associated with deferiprone intake18,19 and one 
with high intravenous doses of deferoxamine.20
Posterior Chamber and Fundus Oculi
In our study sample, 26 eyes (16.25% of the sample) of adult 
patients had non-serious and asymptomatic alterations of 
fundus oculi such as vascular irregularities, retinoschisis, 
pale optic nerve head and increased papillary excavation, 
retinal pigment epithelial alterations or chorioretinal atrophy. 
Logistic regression returned a statistically significant correla-
tion only with deferasirox dosage (p-value 0.006; odds ratio 
[OR] 0.93), ie, a 7% protection factor for every mg/kg/day. 
Multivariate analysis suggested that none of these elements 
was a modifier of drug’s effects (Figure 2.3).
The literature search retrieved 22 articles describing fun-
dus oculi alterations in patients treated with iron chelating 
agents: the only available review described, among the possi-
ble detectable alterations, a pseudoxanthoma-like (PXE) syn-
drome, tortuous vein vessels, degeneration of retinal pigment 
epithelium, retinal hemorrhages, retinal edema, pseudo- 
Figure 2 Statistical analysis of adverse reactions regarding affections of anterior chamber (1), lens (2), fundus oculi (3), myopia (4) and hyperopia (5) onset. Figure shows 
sample presentation (A), correlation analysis (B), logistic regression (C) and multivariate analysis (D). 
Abbreviations: DFX, Deferasirox; DFO, Deferoxamina; DFP, Deferiprone.
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papillitis, macular scars, and a “salt and pepper” retinopathy. 
The study went on to suggest that the use of deferoxamine is 
often associated with macular and/or peripheral pigmentary 
degeneration (“bull’s eye” maculopathy), while deferiprone 
does not seem to be related to retinal toxicity.32 Twelve studies 
found no difference between the patient group receiving last 
generation chelating agents at correct dose and healthy 
group,29,33,34,41 except for the average length of the fundus 
veins.46 More alterations were described in patients who took 
deferoxamine, especially at high doses and 
intravenously.16,30,35–39 Nine case reports described 10 cases 
of fundus alteration related to deferoxamine intake.20–28
Visual Acuity
None of the patients recruited in our study showed 
a significant reduction in BCVA from baseline.
The literature search retrieved 17 articles describing 
visual acuity in chelated patients: six out of eight studies 
found no statistically significant alterations31 and two 
described visual impairments related to deferoxamine 
intake.36,40 Nine case reports described 10 patients taking 
deferoxamine, with visual impairment, sometimes associated 
with maculopathy,21–23 but more often with intravenous 
administration, and retinal pigment epithelium alterations 
that regressed after therapy discontinuation.20,24–28
Refractive Errors and Presbyopia
In our study sample, 52 eyes (32.5% of the sample) had 
mostly mild myopic defects (76.9%). Logistic regression 
returned a statistically significant correlation between 
myopia and chelation therapy (p-value 0.04; OR 1.05), 
ie, a 5% risk increase for each year of treatment. This 
defect appeared to be related to duration of deferoxamine 
therapy (p-value 0.03; OR 1.06), ie, a 6% per annum risk 
increase. Multivariate analysis showed that these results 
were not influenced by any other parameter (Figure 2.4). 
Eight eyes (5% of the total) were affected by mild hyper-
opia. Logistic regression showed no correlation between 
this kind of defect and chelation therapy (Figure 2.5). 
Forty-six eyes (28.75% of the sample) had mostly mild 
astigmatism (78.3%); however, even in this case, the data 
found were not statistically significant (Figure 3.1). 
Figure 3 Statistical analysis of adverse reactions regarding astigmatism (1), presbyopia (2), IOP elevation (3), visual field alterations (4) onset. Figure shows sample 
presentation (A), correlation analysis (B), logistic regression (C) and multivariate analysis (D). 
Abbreviations: DFX, Deferasirox; DFO, Deferoxamina; DFP, Deferiprone.
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Instead, presbyopia affected 36 eyes (22.5% of the sam-
ple). Since all the patients with this visual defect were 
older than 39.5 years, statistical analysis was only per-
formed on these patients to assess whether therapy dura-
tion and doses might be related to the severity of visual 
defect. Results showed a significant correlation between 
presbyopia and total duration of therapy (p-value 0.03; OR 
1.21), ie, a 21% risk increase for each year of treatment 
not influenced by patient age (p-value 0.98). Therefore, 
presbyopia appeared to be connected with the duration of 
deferoxamine therapy (p-value 0.02; OR 1.14), ie, a 14% 
increase in risk per year; Nevertheless, the association 
with deferiprone dose (p-value 0.003; OR 0.97) had 
a protective factor of 3% for each mg/kg/day. 
Multivariate analysis revealed that none of these factors 
modified the parameters (Figure 3.2).
The literature search retrieved only one article41 that 
investigated the frequency of refractive errors and presby-
opia but found that none of these defects were related to 
chelation therapy.
Intraocular Pressure
In our study, IOP was not measured in children less than 
10 years of age (as collaboration of younger patients dur-
ing the exam is difficult). The observed IOL was below or 
equal to 21 mmHg in all other patients. Although IOP 
levels were within the normal range, linear regressions 
were performed to determine whether a correlation existed 
between higher IOP levels and chelation therapy intake: 
only the correlation with the duration of deferoxamine 
therapy was statistically significant (p-value 0.002; asso-
ciation coefficient −0.12), ie, a pressure reduction of 
0.12 mm Hg for each year of treatment (Figure 3.3).
The literature search retrieved two articles describing 
IOP in chelating patients: one study found no difference in 
IOP between patients treated with these drugs and healthy 
patients;30 similarly, a case report of a patient undergoing 
subcutaneous deferoxamine therapy specified that IOP was 
found to be in normal range.27
Visual Field and Mean RNFL Thickness
In our study sample, visual field was evaluated only in 72 
patients (136 eyes), as collaboration by the younger chil-
dren was insufficient for a reliable examination. Ten eyes 
(7.35% of the sample) exhibited visual field alterations: in 
two cases, a narrowing of the upper visual field was 
observed, even if not attributable to treatment, but related 
to blepharochalasis; in the other eight cases (5.9% of the 
sample), a mild and asymptomatic incision in the temporal 
visual field was found. Logistic regression returned no 
significant correlation between visual field anomaly and 
treatment duration and doses (Figure 3.4).
None of the patients recruited in our study showed 
changes in the mean thickness of the RNFL, having all 
obtained values between 98.1 ± 10.9 μm, a range of values 
taken as a reference for normality.
The literature search retrieved nine articles about visual 
field in patients receiving iron chelation therapy: a single 
review described a reduction in the visual field caused by 
deferoxamine.32 Of the four studies involving patients 
treated with deferoxamine, one study did not detect any 
abnormalities,29 while the others reported a narrowed 
visual field (49° vs 61° in the normal population)33 and 
complete resolution of reduced central vision with treat-
ment discontinuation36 and peripheral visual field defects 
resulting from intravenous administration.39 Four case 
reports described five cases of deferoxamine-related altera-
tions such as central and paracentral scotomas20,23,25 or 
marked peripheral constraints and “tunnel vision” in some 
cases,20,26 mostly due to high doses and/or intravenous 
drug administration which improved after therapy discon-
tinuation or dose reduction.
Discussion
The literature on ocular alterations in patients with beta- 
thalassemia is very poor. We were unable to determine 
whether the frequency in our sample is comparable to 
general population. Anterior chamber alterations, the 
only observed abnormality, were not statistically corre-
lated with chelation therapy. Similarly, lens opacities 
were not associated with chelation therapy, although treat-
ment-related cases have been described, probably related 
to either high dosage20 or the particular pharmacokinetics 
of deferiprone.18,19,42 Deferiprone has been shown to 
induce iron shift from the intracellular compartment to 
the extracellular space, resulting in its deposition in the 
aqueous humour and activation of glutathione peroxidase, 
which leads to lens opacification. Cataract prevalence in 
the general population ranges from 0.23% in children47 to 
70% in adults over 75 years of age, with an average 
between 15 and 19%.48 The percentage in our study sam-
ple falls within this range; however, the higher prevalence 
among the children may be due to the small sample size.
Our study shows that iron chelation therapy is not 
associated with fundus alterations; instead, a higher dose 
of deferasirox may even have a protective effect on the 
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fundus oculi (7% per mg/kg/day). The reasons for this 
possible protective effect are currently unknown. 
Therefore, this aspect needs to be investigated with further 
studies.
The literature reports that deferoxamine-related retino-
pathy probably has a multifactorial origin including elec-
trolyte imbalance, with excessive metals removal 
(particularly copper and zinc) from the retina and possible 
iron-damaging effects on the blood-retinal barrier.20 Since 
it is more common in patients receiving higher dosage, 
especially via intravenous administration, it is recom-
mended to maintain the deferoxamine therapeutic index 
below 0.025 and to perform periodic ophthalmological 
exams.24 In contrast, the increased length and tortuosity 
of venous vessels may be related to hematocrit reduction 
due to TM rather than chelation therapy.46 The prevalence 
of retinal anomalies is common in the general population; 
the most frequent form, however, is age-related macular 
degeneration in patients over 55 years old.49 Since our 
patients were 50 years old at most, we cannot say that 
their alterations were related to this condition. 
Accordingly, chelation therapy was excluded from among 
possible causes. Nonetheless, a recent study,50 published 
after completion of our study, reported that some beta- 
thalassemic patients receiving chelating therapy, without 
presenting any visible defects, showed electroretinogram 
alterations. A potential future area of focus for further 
study should consider this examination as a possible tool 
for identifying early alterations, even in asymptomatic 
patients.
None of our patients exhibited non-correctable altera-
tions in visual acuity, demonstrating that chelating therapy 
(with subcutaneous deferoxamine or oral deferiprone or 
deferasirox at low doses calibrated to ferritin levels) is safe 
for retina and optic nerve function. The literature only 
describes the toxic effects of deferoxamine taken in excess 
when compared to the amount of available iron, as the 
unbound drug can accumulate in tissues, inhibiting DNA 
synthesis. On the contrary, a subcutaneous dose of 50 mg/ 
kg seems to be safe,36 whereas patients who, in acute 
situations, require intravenous administration (a rare even-
tuality in current times thanks to the availability of other 
chelating agents) should not exceed the maximum dose of 
125 mg/kg/day.20
Among the parameters evaluated, refractive errors 
were the most frequent (51% of the sample). While none 
of the three drugs had any influence on the development of 
hyperopia and astigmatism, the duration of iron chelation 
therapy could be a risk factor for the development of 
myopia (5% per year of treatment). Deferoxamine in par-
ticular was proved to be a risk factor if continued for 
a long time (risk of 6% per annum). The prevalence of 
myopia in the Caucasian population is 33.1%; likewise, 
the prevalence of hyperopia ranges from 3 to 57% and 
the one related to astigmatism is 46%.51 In our sample, the 
prevalence of patients with refractive errors fell within the 
general population averages.
Our findings suggest that while total chelation therapy 
duration is not related to the severity of presbyopia, pro-
longed deferoxamine therapy increases the risk of early 
development by 14% per year. Conversely, a higher defer-
iprone dose, which ensures better ferritin control, could be 
considered as a protective factor (3% protection factor 
per mg/kg/day). The prevalence of presbyopia in our sam-
ple fell within the range for the general population. 
Presbyopia has its natural onset between age 40 and 50 
years and the risk of developing it with advancing age is 
100%.52,53
For intraocular pressure, we found no abnormal IOP 
values. Though all were ≤21 mmHg, statistical analysis to 
assess the correlation between chelation and IOP values 
around the upper limits of normality suggested that pro-
longed therapy with these drugs is not related to ocular 
hypertension. On the contrary, continued use of deferox-
amine could have a protective effect, with reduced IOP 
levels by 0.12 mmHg per year of treatment. The fact that 
some patients reached the upper normality limit of 21 
mmHg could be attributed to the measurement method: 
air tonometry tends to overestimate IOP as it induces 
a reflexive contraction of ocular and eyelid muscles.
Finally, statistical analysis of visual field alterations 
was very important in determining how low doses of 
subcutaneous deferoxamine or oral chelating agents did 
not cause significant disturbances, despite the lack of 
information regarding their distribution in the general 
population. In most published cases, abnormalities have 
been associated with the use of high-dose deferoxamine 
administered intravenously.
This study offers a hint for the enhancement of the 
drug database regarding the side effects in the ophthalmol-
ogy field of these therapies.
A limitation of the present study is represented by the 
limited sample size. It is hoped that in the future this topic, 
on which little scientific evidence exists, can be thor-
oughly investigated with clinical trials with a greater num-
ber of patients.
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In conclusion, our study shows that modern chelation 
therapy is not associated with particular alterations in 
visual function: only myopia and premature presbyopia 
could be related to prolonged treatment with deferoxa-
mine, while deferiprone, if taken at higher doses, plays 
a protective role against premature presbyopia. Based on 
our data, we can conclude that limiting deferoxamine 
treatment can help prevent ocular complications. In 
patients with TM, the use of deferiprone and/or defera-
sirox may be preferable and deferiprone, in particular, in 
patients over age 40 years. The prevalence of visual 
defects in our patients was lower than the mean rate in 
the general population: this suggests that correct manage-
ment of therapy can play an important prevention role 
against the development of the majority of ocular 
alterations.
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